In terms of immunotherapy, our study found that the low-risk group with breast cancer showed higher PD-1 expression levels, greater infiltration of CD8+ T cells and NK cells, and higher IPS, suggesting that these patients might benefit more from ICIs treatment. This evidence concerns the gene PDCD1 and breast carcinoma.